Primary Ewing's sarcoma of the temporal bone: a rare oncological enigma

Authors

  • Arunabha Chakravarti Department of Otorhinolaryngology and Head and Neck Surgery, Lady Hardinge Medical College and Associated Hospitals, New Delhi, Delhi, India https://orcid.org/0000-0002-3972-0254
  • Akhil Bahuguna Department of Otorhinolaryngology and Head and Neck Surgery, Lady Hardinge Medical College and Associated Hospitals, New Delhi, Delhi, India
  • Kiran Agrawal Department of Pathology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, Delhi, India

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20250125

Keywords:

Neuroectodermal malignancy, Chemotherapy, Facial nerve palsy

Abstract

Ewing's sarcoma is an uncommon neuroectodermal malignancy that rarely develops in the temporal bone. The early clinical recognition and definitive management of this condition pose unique challenges. This report presents a case of a 4-year-old girl with right ear pain, right post-aural swelling and progressively increasing right-sided facial nerve palsy for the past 6 months. High-resolution computed tomography (HRCT) temporal bone revealed an ill-defined soft tissue lytic lesion epi centred in the right mastoid extending to the external auditory canal and intracranially. Microscopic sections revealed round blue cells which were strongly positive for CD-99. The diagnosis of primary Ewing's sarcoma of the temporal bone was made. Considering the intracranial extension of the tumour, chemotherapy as the first line of treatment was initiated and 9 cycles have been administered resulting in marked regression of the tumour. A range of nonspecific symptoms, such as otalgia, otorrhea, sensorineural hearing loss, post aural mass, and facial nerve palsy, are indicative of the clinical manifestation of primary Ewing's sarcoma in the temporal bone. Because of how subtle these symptoms are, more clinical knowledge is required, especially in light of the small number of documented cases. When children and adolescents present with similar symptoms, clinicians should rule out Ewing's sarcoma even though it is a rare entity.

 

Metrics

Metrics Loading ...

Author Biography

Kiran Agrawal, Department of Pathology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, Delhi, India

Director Professor & Head

Department of Pathology (Lady Hardinge Medical  College, New Delhi)

MBBS

MD (Pathology)

References

Watanabe H, Tsubokawa T, Katayama Y, Koyama S, Nakamura S. Primary Ewing’s sarcoma of the temporal bone. Surg Neurol. 1992;37(1):54-8. DOI: https://doi.org/10.1016/0090-3019(92)90067-W

Stiller CA, Bunch KJ, Lewis IJ. Ethnic group and survival from childhood cancer: report from the UK Children’s Cancer Study Group. Br J Cancer. 2000;82(7):1339-43. DOI: https://doi.org/10.1054/bjoc.1999.1101

Kadar A, Hearst M, Collins M, Mangano F, Samy R. Ewing’s Sarcoma of the Petrous Temporal Bone: Case Report and Literature Review. Skull Base. 2010;20(03):213-7. DOI: https://doi.org/10.1055/s-0029-1246224

Choudhury KB, Sharma S, Kothari R, Majumder A. Primary extraosseous intracranial Ewing′s sarcoma: Case report and literature review. Indian J Med Paediatr Oncol. 2011;32(02):118-21. DOI: https://doi.org/10.4103/0971-5851.89798

Vishnoi JR, Kumar V, Srivastava K, Misra S. Primary Ewing’s sarcoma of the temporal bone: a rare entity and review of the literature. BMJ Case Rep. 2019;12(10):e230768. DOI: https://doi.org/10.1136/bcr-2019-230768

Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children’s Oncology Group. J Clin Oncol. 2012;30(33):4148-54. DOI: https://doi.org/10.1200/JCO.2011.41.5703

Desai SS, Jambhekar NA. Pathology of Ewing’s sarcoma/PNET: Current opinion and emerging concepts. Indian J Orthop. 2010;44(4):363-8. DOI: https://doi.org/10.4103/0019-5413.69304

Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing’s Sarcoma: Standard and Experimental Treatment Options. Curr Treat Options in Oncol. 2009;10(1-2):126-40. DOI: https://doi.org/10.1007/s11864-009-0104-6

Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, et al. Results of the EICESS-92 Study: Two Randomized Trials of Ewing’s Sarcoma Treatment—Cyclophosphamide Compared WithIfosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients. J Clin Oncol. 2008;26(27):4385-93. DOI: https://doi.org/10.1200/JCO.2008.16.5720

Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, et al. Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing’s Sarcoma and Primitive Neuroectodermal Tumor of Bone. N Engl J Med. 2003;348(8):694-701. DOI: https://doi.org/10.1056/NEJMoa020890

Downloads

Published

2025-01-27

How to Cite

Chakravarti, A., Bahuguna, A., & Agrawal, K. (2025). Primary Ewing’s sarcoma of the temporal bone: a rare oncological enigma . International Journal of Otorhinolaryngology and Head and Neck Surgery, 11(1), 88–91. https://doi.org/10.18203/issn.2454-5929.ijohns20250125